Caltech/UCLA Individualized Theranostic Engineering to Advance Metabolic System (iTEAM)

加州理工学院/加州大学洛杉矶分校个性化治疗诊断工程促进代谢系统 (iTEAM)

• 批准号: 10213026
• 负责人: Dino Di Carlo
• 金额: $ 29.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-08 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10213026
• 关键词: Engineering; Metabolic; System; theranostics

ABSTRACT The California Institute of Technology (Caltech) and the University of California at Los Angeles (UCLA) have partnered to integrate advanced imaging and sensing coupled with computing needed to translate technological innovation to address the global cardiometabolic disease. The UCLA/Caltech integrated Theranostic Engineering to Advance Metabolic Medicine (iTEAM) Program represents a new paradigm that will be formalized into a 2-year, structured curriculum with an emphasis on recruiting the under-represented post-doctoral engineers or physical scientists into leadership roles in academia and industry. The convergence of the fundamental strengths of Caltech and clinical strengths of UCLA is conducive to individualize training in 1) advanced sensing or 2) imaging coupled with computing to address 3) cardiometabolic disease. The iTEAM program is partnering with industry leaders (Amgen, Johnson & Johnson, Medtronic, and Edwards Lifesciences) for internship, mentorship, and leadership programs. Both the Caltech Diversity Center and UCLA Faculty Diversity & Development Office have supported workshops on Science Technology Engineering & Mathematics (STEM) for women and underrepresented minorities. To implement this UCLA/Caltech iTEAM program, we have developed a mentoring and self-evaluating structure in the inclusion of 21 primary and co-mentors, 13 consulting mentors, and 10 industry leaders (42% female). Each iTEAM scholar will have co-mentorships: a primary mentor from enabling technologies and a secondary from cardiometabolic medicine and/or industry. In Year 1, iTEAM scholars will: 1) Participate in an initial two- day workshop including mentors, program leaders, clinicians, physician-scientists, and industry leaders to explore projects, expectations, mentorship, and goals; 2) Meet one-to-one with the Program Director(s) to finalize a primary (imaging or sensing) and a co-mentor (cardiometabolic disease or industry); 3) Develop an Individualized Development Plans (IDP) with the Advising & Training Committee to finalize the project; and 4) Strengthen fundamental knowledge in advanced imaging, sensors, or computation and didactic training for ethics in biomedical research and publications. In Year 2, iTEAM scholars will be afforded 1) the opportunity to present work-in-progress and provide feedback in quarterly meetings with a primary mentor and with a co- mentor, 2) an option to participate in a certificate in Pathways in Clinical and Translational Research from the UCLA Clinical Translational Science Institute (CTSI) or Law and Technology for FDA regulatory science (BE188/299); and/or 3) to participate in UCLA CTSI-sponsored professional development in preparation for an academic or industry career. Both Caltech and UCLA Deans have committed matching funds for each iTEAM scholar. UCLA Vice Provost for Graduate Education and has also committed supplemental trainee support to enhance the diversity of trainees. Overall, this program infuses the scientific workforce with the next generation of theranostic bioengineers prepared to solve the worldwide threat of cardiometabolic disease.

抽象的 加利福尼亚理工学院（加州理工学院）和加利福尼亚大学洛杉矶大学（UCLA）有 合作以整合高级成像和传感以及翻译所需的计算 解决全球心脏代谢疾病的技术创新。 UCLA/CALTECH集成 促进代谢医学（ITEAM）计划的疗法工程代表了一种新的范式 将正式化为2年的结构化课程，重点是招募不足的人 博士后工程师或物理科学家在学术界和工业中担任领导角色。这 加州理工学院的基本优势和UCLA临床强度的融合有利于 在1）高级感应中的个性化培训或2）成像与计算以解决3） 心脏代谢疾病。 ITEAM计划正在与行业领导者合作（Amgen，Johnson＆ 约翰逊，Medtronic和Edwards Lifesciences）实习，指导和领导力计划。两者 加州理工学院多样性中心和加州大学洛杉矶分校的教职员工多样性与发展办公室已支持有关 妇女和代表性不足的少数民族的科学技术工程与数学（STEM）。到 实施此UCLA/CALTECH ITEAM程序，我们在 包括21位主要和联合给出者，13位咨询导师和10位行业领导者（女性为42％）。 每个ITEAM学者都将拥有会议：启用技术的主要导师和次要的 来自心脏代谢药物和/或行业。在第1年，ITEAM学者将：1）参加最初的两个 一日研讨会，包括导师，计划负责人，临床医生，医师科学家和行业领导者 探索项目，期望，指导和目标； 2）与计划主管一对一会见 最终确定主要（成像或传感）和一个同事（心脏代谢疾病或工业）； 3）开发一个 咨询与培训委员会的个性化发展计划（IDP），以最终确定该项目；和4） 加强对高级成像，传感器或计算和教学培训的基本知识 生物医学研究和出版物中的伦理。在第二年，ITEAM学者将获得1） 目前正在进行工作，并在与主要导师的季度会议中提供反馈，并与 导师，2）参与临床和转化研究途径证书的一种选择 UCLA临床转化科学研究所（CTSI）或FDA监管科学的法律与技术 （BE188/299）;和/或3）参加UCLA CTSI赞助的专业发展，为 学术或行业职业。加州理工学院和加州大学洛杉矶分校的院长都为每个iteam提供了匹配资金 学者。加州大学洛杉矶分校的研究生教育副教务长，还向补充学员提供支持 增强学员的多样性。总体而言，该计划注入了下一代的科学劳动力 准备解决全球心脏代谢疾病威胁的治疗生物工程师。